Cited by 603Diabetes Management and ResearchDiabetes Treatment and ManagementPeripheral Neuropathies and Disorders

The DOI matches its Crossref record.

The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy

The Diabetes Control and Complications Trial Research Group.·1995·Annals of Internal Medicine

Abstract

OBJECTIVE: To examine whether intensive therapy designed to achieve glycemic levels as close to normal as possible prevents or slows the progression of neuropathy when compared with conventional therapy in patients with insulin-dependent diabetes mellitus in the Diabetes Control and Complications Trial. DESIGN: Multicenter, randomized, controlled clinical trial. SETTING: 29 U.S. and Canadian clinical centers. PARTICIPANTS: 1441 patients aged 13 to 39 years, of whom 726 had had insulin-dependent diabetes mellitus for 1 to 5 years and had no retinopathy at baseline (primary prevention cohort); 715 had had diabetes for 1 to 15 years and had minimal to moderate nonproliferative retinopathy at baseline (secondary intervention cohort). INTERVENTION: Intensive therapy with three or more daily insulin injections or continuous subcutaneous insulin infusion guided by four or more glucose tests per day compared with conventional therapy with one or two daily insulin injections. RESULTS: Intensive therapy reduced the development of confirmed clinical neuropathy (defined as a history or physical examination consistent with clinical neuropathy confirmed by either abnormal nerve conduction or autonomic nervous system testing) by 64% (95% CI, 45% to 76%) in the combined cohorts after 5 years of follow-up (5% of the intensive therapy group compared with 13% of the conventional therapy group). The prevalence of abnormal nerve conduction and abnormal autonomic nervous system function were reduced by 44% (CI, 34% to 53%) and 53% (CI, 24% to 70%), respectively (26% of the intensive treatment group developed abnormal nerve conduction compared with 46% of the conventional treatment group; 4% of the intensive treatment group had abnormal autonomic nervous system function compared with 9% of the conventional treatment group). Finally, nerve conduction velocities generally remained stable with intensive therapy but decreased significantly with conventional therapy. CONCLUSION: Intensive diabetes therapy markedly delays or prevents the development of clinically manifest diabetic polyneuropathy as confirmed by objective nerve function testing in patients with insulin-dependent diabetes mellitus.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-122-8-199504150-00001

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 401–500 of 603

Metadata

Authors
The Diabetes Control and Complications Trial Research Group.
Corresponding author
The Diabetes Control and Complications Trial Research Group.
Venue
Annals of Internal Medicine
Published
1995-04-15
Volume
122
Issue
8
Pages
561-568
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W4245107010
Cited by
602
References
0
Citations by year
2026: 7 · 2025: 5 · 2024: 10 · 2023: 15 · 2022: 22 · 2021: 18 · 2020: 17 · 2019: 10 · 2018: 24 · 2017: 22 · 2016: 24 · 2015: 19 · 2014: 25 · 2013: 23 · 2012: 24
FWCI
8.76
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Keywords
intensive diabetes therapy, diabetic neuropathy, diabetic polyneuropathy, type 1 diabetes, glycemic control, insulin pump therapy, multiple daily insulin injections, nerve conduction velocity, autonomic dysfunction, neuropathy prevention, Diabetes Control and Complications Trial
MeSH terms
Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Follow-Up Studies, Humans, Infusion Pumps, Insulin Infusion Systems, Neural Conduction, Patient Compliance, Prospective Studies, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review